Table 1.
The drugs being assessed and the arrhythmia related events occurred post drug administration
| Drug name | Note | Proarrhythmia risk | Arrhythmia-related events (253G1) | Arrhythmia-related events (iCell2) |
|---|---|---|---|---|
| isoproterenol | β adrenoceptor agonist | Low | N/A | N/A |
| verapamil | calcium blocker | Low | Cessation in 3/6 (Control), 4/6 (TW) | Cessation in 0/6 (Control), 1/4 (TW) |
| ranolazine | sodium and hERG blocker | Low | EAD in 2/6 (Control) in 1/6 (TW), Cessation in 3/6 (Control), 0/6 (TW) | EAD in 3/8 (Control) in 1/9 (TW), Cessation in 2/8 (Control), 1/9 (TW) |
| E4031 | potassium blocker | Low | N/A | N/A |
| mexiletine | sodium channel and hERG channel blocker | Low | Arrhythmic activities in 1/9 (Control and TW) | Arrhythmic activities in 2/8 (Control), 0/9 (TW) |
| pimozide | hERG blocker | Intermediate | Arrhythmic activities in 0/4 (Control), 2/4 (TW) | N/A |
| quinidine | hERG blocker | high | Arrhythmic activities in 1/5 (Control), 3/4 (TW) | N/A |
| aspirin | negative control | N/A | N/A | N/A |